AirSculpt Technologies (AIRS) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue declined 13.7% year-over-year to $44 million, with case volume down 14.1% to 3,392 cases, reflecting industry weakness and macroeconomic pressures.

• Net loss narrowed to $0.6 million from $3.2 million in Q2 2024; adjusted EBITDA was $5.8 million (13.3% margin), compared to $6.9 million (13.5%) last year.

• Strategic and transformation initiatives included marketing optimization, sales process improvements, expanded financing, new product offerings, and piloting a skin tightening procedure.

• Cost reduction program targeting $3 million in annual savings was implemented, with new center openings paused.

• CFO Dennis Dean announced retirement and will remain until a successor is appointed.

Financial highlights

• Q2 2025 revenue was $44 million, down 13.7% year-over-year; same-store revenue declined 22%.

• Adjusted EBITDA was $5.8 million (13.3% margin), down from $6.9 million (13.5%) in Q2 2024.

• Adjusted net income was $1.2 million, or $0.02 per diluted share.

• Cash and cash equivalents at quarter-end were $8.2 million, with $5 million available under the revolving credit facility.

• Debt was reduced by $16 million in Q2, with total debt at $57.7 million as of June 30, 2025.

Outlook and guidance

• Full-year 2025 revenue guidance affirmed at $160–$170 million; adjusted EBITDA expected between $16–$18 million.

• No new center openings planned for 2025; focus remains on strengthening same-store sales.

• Management expects continued industry headwinds but anticipates benefits from strategic initiatives and cost reductions in H2 2025 and 2026.

• Company believes cash from operations will be sufficient for liquidity and debt obligations for at least the next 12 months.